|
|
 |
|
Viewing report
|
|
|
|
European Point of Care (POC) Infectious Disease Market
Frost & Sullivan, Dec 2008, Pages: 82
This research service gives a detailed analysis of the European point of care (POC) infectious disease market from 2008-2015.
This Frost & Sullivan research service titled European Point of Care (POC) Infectious Disease Market provides an overview of the market, together with the revenue generated in Europe for 2008 and forecasted for 2015. In addition, it provides a complete analysis of key drivers, challenges, and trends in the market. Finally, it provides strategic solutions to vendors to gain advantage in this growing market and opportunities in Europe. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markers: HIV-AIDS, sexually transmitted diseases (Chlamydia and Gonorrhea), Strep A and C-reactive protein (CRP). The following technologies are also covered: point-of-care tests, including hand-held devices (test strips and cassettes) and desktop analysers.
Multiple Benefits Support Widening Adoption of POCT
Recent discoveries and innovations in the realm of molecular diagnostics hold the exciting promise of revolutionising the healthcare arena. “In particular, the evolution of POC testing is expected to have a significant impact on patient care management,” notes the analyst of this research. “Additionally, public awareness initiatives and governmental campaigns across Europe are facilitating the uptake of new technologies and highlighting the value of POC molecular diagnostics in the improvement of medical care, reducing overall healthcare costs.” One of the drivers associated with the growth of POC testing is the need for clinicians to quickly test results in settings where patient treatment decisions benefit from immediate diagnostic findings such as hospital emergency rooms and physician offices. “The market for POC diagnostic tests is growing rapidly,” adds the analyst of this research. “Public health policy makers, insurers and governments are becoming more aware of the need to test for certain infectious diseases.” Healthcare authorities such as the FDA, Centre for Disease Control (CDC) and WHO have recognised that certain rapid POC products are not only easier to use, reliable, sensitive and specific, but that they also can be more cost-effective than traditional diagnostic tests performed in the central laboratory.
POC testing helps provide better patient care by aiding physicians in making informed decisions during emergencies. This will enable the start of immediate treatment for many conditions. It will also reduce the strain on resources in secondary care, resulting in reduced outpatient clinic time, which benefits both parties. “POC device manufacturers need to promote instruments that provide results that are as accurate and reliable as those obtained from laboratories, while also demonstrating their cost-effectiveness to physicians and patients,” advises the analyst of this research. “However, they can only do so by channelling substantial resources into research and development and develop devices that are accurate, reliable and easy-to-use and provide quicker turn-around-time (TAT).”
Personnel Training Critical to Ensure Optimal Use of POCT
The primary concern articulated by most of the healthcare practitioners is the importance of ensuring the accuracy and reliability of POC test machines. In order to ensure accuracy, quality control is seen as important, including the training of personnel who routinely use the POC tests. The issue of cost is at the core of the POC tests and will ultimately dictate decisions regarding the implementation of the technology. The cost associated with staff performing extra duties could be a potential barrier; ensuring POC test quality is a resource-intensive endeavour that involves co-ordinating a variety of devices, locations and staff. The successful implementation and management of POC programmes in a hospital depends on the formation of a standing committee. This committee must be empowered by every level of administration to review all POC testing requests, to select instrumentation to be evaluated and to coordinate the oversight of existing and new POC testing programmes, all within the hospital budget.
“For POC devices, the principal technology challenges will continue to be in test chemistry,” comments the analyst of the research. “This core science must facilitate laboratory quality test results while requiring minimal training for users as well as little or no calibration and maintenance.” Today, user training becomes all the more important in order to meet the standards of laboratory testing. Hospitals should organise regular training programmes in collaboration with diagnostic device manufacturers to train staff that use the POC instrument regularly. At the same time, the successful establishment of a market for a new test would have marketing demands that are too high and timelines that are too long. Hence, the ideal option for diagnostic companies would be to partner with pharmaceutical firms and focus on those tests that have a clear link to specific therapies, in addition to having an immediate or prospective clinical potential.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The Emerging European Molecular POC Testing Markets
Push to Talk over Cellular (PoC): Business Opportunities and Challenges
Push to Talk over Cellular (PoC) Market Opportunities, Strategies, and Forecasts 2007 to 2013
Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies
The Top 40 Manufacturers Of Point-Of-Care Diagnostics For Infectious Diseases
Key Sub-Saharan African Infectious Disease Pharmaceutical Markets
Infectious Immunology Test Reagents Clinical Trial Analysis
The Top 40 Manufacturers In Europe Of In Vitro Diagnostics For Infectious Diseases
Infectious Diseases Drugs Markets
Point of Care Coagulation Testing in Europe
U.S. Infectious Disease Diagnostics Markets
An Evaluation of Product Usage for Molecular Testing within Infectious Diseases - Europe
|
|
|
|
